In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

News from the Young Thrombosis Group - September update

Highlights from the ESC Congress 2021 – a Young Thrombosis Researcher’s viewpoint

Whilst it was a shame not to be able to meet in person, the ESC Congress 2021 – The Digital Experience offered a vivid, navigable platform to experience the very latest results and opinions in our field.

The results of several large, multicentre trials of antithrombotic therapy were revealed. For example, MASTER DAPT supported the hypothesis that, in those at high risk of bleeding undergoing percutaneous coronary intervention with the latest generation of drug-eluting stents, shortening DAPT to one month then offering antiplatelet monotherapy appears to be safe and reduced bleeding compared to standard-of-care durations. STOPDAPT2-ACS, on the other hand suggested that, in a broader population, we likely can’t push the concept of de-escalating to P2Y12-inhibitor monotherapy shortly after PCI too far if using clopidogrel, which has significant interindividual variability in effect.

There were so many other sessions of relevance to our field to choose from. A notable and lively highlight was the Great debate: To reduce the risk of bleeding after PCI – Shorten DAPT!, which complemented the theme explored by the studies above. The pros and cons of this statement were elegantly argued by Professors Marco Valgimigli and Rob Storey respectively and though forced to ‘take sides’, the session came to a balanced conclusion.

Finally, it was fantastic to see the range of high-quality contributions from Young Thrombosis Researchers. In particular, there were four very impressive finalists for the Young Investigator Award in the Thrombosis, Platelets and Coagulation category. Nicely illustrating the breadth of the field, the presentations covered mechanistic aspects (Luca Liberale from the University of Zurich, Switzerland), clinical imaging techniques (Evangelos Tzolos, University of Edinburgh, UK), novel antithrombotic agents (Fawaz Alenazy, University of Birmingham, UK) and the link between thrombosis and inflammation after COVID-19 infection (Loes Willems, Radboud University Medical Centre, The Netherlands). Special congratulations should be offered to Dr Tzolos, who won the Award.

Young Investigator Awards.png